The Anti-Infective Drugs Market is expected to register a CAGR of 1.2% from 2025 to 2031, with a market size expanding from US$ XX Million in 2024 to US$ XX Million by 2031.
The research report on the Anti-Infective Drugs Market is segmented by drug class into antibiotics, antivirals, antifungals, and antiparasitics. Applications analyzed include bacterial infections, viral infections, fungal infections, and parasitic infections. End-users include hospitals, specialty clinics, pharmacies, and research institutions. The regional analysis covers key markets such as North America, Europe, Asia Pacific, the Middle East and Africa, and South America. The market evaluation is presented in US$ for all segmental analyses.
Purpose of the ReportThe report Anti-Infective Drugs Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Anti-Infective Drugs Market Segmentation
Type- RIDT
- Viral Culture
- DFA
- Serological Assays
- Hospitals
- Clinical Laboratories
Strategic Insights
Anti-Infective Drugs Market Growth Drivers- Increasing Infectious Diseases Prevalence Globally: Increased cases of infectious diseases, for example, bacterial infections, fungal infections, viral diseases, including influenza, hepatitis, and HIV and parasitic infections are among the growth factors in the anti-infective drugs market. Increased cases of infectious diseases are caused by various factors, including increased urbanization, climate change, antimicrobial resistance, and international travel. Furthermore, new and re-emerging infectious diseases, including drug-resistant tuberculosis and hospital-acquired infections have led to increased demand for effective anti-infective drugs.
- Emergence of Concern about Antimicrobial Resistance (AMR): With the increase in misuse and overuse of antibiotics, AMR has now emerged as a serious threat to the global health domain. As such, there has been significant investment by governments and healthcare institutions into R&D, creating new classes of anti-infective drugs, novel antibiotics, antifungals, and antivirals. WHO and agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are highly encouraging new drug development initiatives. This is providing a conducive atmosphere for market growth.
- Government and Private Sector Investment in R&D are on the Rise: A great amount of effort is being made both by governments and private pharmaceutical companies in the development of new anti-infective drugs, especially those targeting drug-resistant pathogens. The Global Antibiotic Research & Development Partnership (GARDP) and the Biomedical Advanced Research and Development Authority (BARDA) funding are some of the public-private partnerships and incentives that are pushing innovation in this area. These investments are hastening the development of next-generation anti-infective therapies-from combination drugs to precision-targeted antibiotics.
- Expansion of Broad-Spectrum and Targeted Anti-Infective Drugs: The market is witnessing an increasing focus on both broad-spectrum and targeted anti-infective drugs. Broad-spectrum antibiotics remain essential for treating infections when the exact pathogen is unknown, especially in emergency settings. However, targeted therapies are gaining traction as they minimize the risk of resistance development and preserve healthy microbiota. For example, the rise of narrow-spectrum antibiotics such as fidaxomicin for Clostridioides difficile infections demonstrates a shift towards precision medicine in infectious disease treatment. Similarly, targeted antiviral therapies such as monoclonal antibodies and small-molecule inhibitors are being developed for diseases like hepatitis B and HIV. As research advances in genomics and diagnostics, the trend toward personalized anti-infective therapy will likely accelerate, enhancing treatment efficacy while reducing resistance risks.
- Growing Investment in Antiviral and Antifungal Therapies:
While antibiotics have traditionally dominated the anti-infective drugs market, there is a growing focus on antiviral and antifungal treatments due to the rising incidence of viral infections and fungal diseases. The COVID-19 pandemic highlighted the urgent need for antiviral drugs, leading to the rapid development of therapies such as remdesivir and molnupiravir. Beyond COVID-19, the increasing global prevalence of hepatitis, influenza, and HIV/AIDS is driving investment in antiviral research. The World Health Organization (WHO) estimates that 296 million people worldwide were living with chronic hepatitis B in 2019, necessitating long-term antiviral treatment. Additionally, fungal infections, often overlooked, are becoming a growing concern, particularly among immunocompromised patients. The CDC reports that cases of invasive Candida auris, a multidrug-resistant fungal infection, have risen sharply in recent years. As a result, pharmaceutical companies are investing more in developing novel antifungal agents, such as echinocandins and azole-based therapies. - Shift Toward Combination Therapies:
Combination therapies, where multiple drugs are used simultaneously to treat infections, are becoming a key trend in the anti-infective drugs market. This approach is particularly effective in addressing drug resistance and improving treatment outcomes. For instance, combination antibiotic therapies are commonly used for tuberculosis and HIV, reducing the risk of resistance and enhancing efficacy. The success of combination antiretroviral therapy (ART) in HIV treatment, which has transformed HIV from a fatal disease into a manageable condition, has set a precedent for other infectious diseases. The trend is also extending to bacterial infections, where drug combinations such as ceftazidime-avibactam (for multidrug-resistant Gram-negative infections) are being increasingly adopted. As drug resistance continues to challenge traditional monotherapies, the market will see further growth in combination drug development across bacterial, viral, and fungal infections.
- Growing in Popularity are Non-Traditional Anti-Infective Therapies:
Alternative anti-infective therapies, including bacteriophage therapy, antimicrobial peptides, and microbiome-based treatments, are of interest in light of increasing antibiotic resistance. Bacteriophage therapy, for instance, utilizes viruses that infect and kill bacteria. This has emerged as a possible solution for treating multidrug-resistant infections. Expanding research also includes antimicrobial peptides, which target bacteria, fungi, and viruses with relatively lower resistance potential. The therapies that make use of restoration of gut and skin microbiota to combat infection are also taking center stage, and companies interested in these areas can differentiate their offerings in a market where resistance is growing faster than the potential for new remedies.
- Pediatric and geriatric anti-infective drug development: The group most affected by infectious diseases includes children and elderly people, although the efforts on drug development have been aimed more at adults. The need for pediatric formulations such as liquid antibiotics and dispersible tablets is growing, particularly in developing countries. Similarly, the geriatric population, more prone to infections because of weak immunity, also requires age-specific formulations. The trend of aging population worldwide would see pharmaceutical companies working on age-specific formulations of anti-infective drugs at an advantageous position in the market.
- Integration of AI and Machine Learning in Drug Discovery:
Artificial intelligence (AI) and machine learning (ML) are revolutionizing the drug discovery and development process for anti-infective drugs. AI-driven models can predict drug resistance patterns, identify novel antimicrobial compounds, and optimize clinical trials. Companies that use AI for anti-infective drug development can speed up the R&D process, reduce costs, and increase the chances of discovering effective new treatments. With increasing adoption of AI in pharmaceuticals, it will be one of the key factors that will define the future of the anti-infective drugs market.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Anti-Infective Drugs Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Anti-Infective Drugs Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Anti-Infective Drugs Market is expected to register a CAGR of 1.2% from 2025-2031.
The major driving factors supporting the Anti-Infective Drugs Market growth are- Increasing Infectious Diseases Prevalence Globally and Emergence of Concern about Antimicrobial Resistance (AMR)
Key Future Trends in the Anti-Infective Drugs Market are- Expansion of Broad-Spectrum and Targeted Anti-Infective Drugs and Growing Investment in Antiviral and Antifungal Therapies
Key companies in the Anti-Infective Drugs Market are - Merck & Co., Inc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Johnson & Johnson Services, Inc, GlaxoSmithKline plc, Hetero, Mylan N.V., Aurobindo Pharma, Cipla Inc
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on request are additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Anti-Infective Drugs Market - By Drug Type
1.3.2 Anti-Infective Drugs Market - By Route of Administration
1.3.3 Anti-Infective Drugs Market - By Indication
1.3.4 Anti-Infective Drugs Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ANTI-INFECTIVE DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ANTI-INFECTIVE DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ANTI-INFECTIVE DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. ANTI-INFECTIVE DRUGS - GLOBAL MARKET OVERVIEW
6.2. ANTI-INFECTIVE DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. ANTI-INFECTIVE DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DRUG TYPE
7.1. OVERVIEW
7.2. DRUG TYPE MARKET FORECASTS AND ANALYSIS
7.3. ANTIBIOTICS
7.3.1. Overview
7.3.2. Antibiotics Market Forecast and Analysis
7.4. ANTIVIRALS
7.4.1. Overview
7.4.2. Antivirals Market Forecast and Analysis
7.5. ANTIFUNGALS
7.5.1. Overview
7.5.2. Antifungals Market Forecast and Analysis
7.6. OTHERS
7.6.1. Overview
7.6.2. Others Market Forecast and Analysis
8. ANTI-INFECTIVE DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - ROUTE OF ADMINISTRATION
8.1. OVERVIEW
8.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
8.3. ORAL
8.3.1. Overview
8.3.2. Oral Market Forecast and Analysis
8.4. TOPICAL
8.4.1. Overview
8.4.2. Topical Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. Others Market Forecast and Analysis
9. ANTI-INFECTIVE DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - INDICATION
9.1. OVERVIEW
9.2. INDICATION MARKET FORECASTS AND ANALYSIS
9.3. HIV INFECTIONS
9.3.1. Overview
9.3.2. HIV Infections Market Forecast and Analysis
9.4. PNEUMONIA
9.4.1. Overview
9.4.2. Pneumonia Market Forecast and Analysis
9.5. HEPATITIS
9.5.1. Overview
9.5.2. Hepatitis Market Forecast and Analysis
9.6. HERPES SIMPLEX VIRUS
9.6.1. Overview
9.6.2. Herpes simplex virus Market Forecast and Analysis
9.7. INFLUENZA
9.7.1. Overview
9.7.2. Influenza Market Forecast and Analysis
9.8. OTHERS
9.8.1. Overview
9.8.2. Others Market Forecast and Analysis
10. ANTI-INFECTIVE DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Anti-Infective Drugs Market Overview
10.1.2 North America Anti-Infective Drugs Market Forecasts and Analysis
10.1.3 North America Anti-Infective Drugs Market Forecasts and Analysis - By Drug Type
10.1.4 North America Anti-Infective Drugs Market Forecasts and Analysis - By Route of Administration
10.1.5 North America Anti-Infective Drugs Market Forecasts and Analysis - By Indication
10.1.6 North America Anti-Infective Drugs Market Forecasts and Analysis - By Countries
10.1.6.1 United States Anti-Infective Drugs Market
10.1.6.1.1 United States Anti-Infective Drugs Market by Drug Type
10.1.6.1.2 United States Anti-Infective Drugs Market by Route of Administration
10.1.6.1.3 United States Anti-Infective Drugs Market by Indication
10.1.6.2 Canada Anti-Infective Drugs Market
10.1.6.2.1 Canada Anti-Infective Drugs Market by Drug Type
10.1.6.2.2 Canada Anti-Infective Drugs Market by Route of Administration
10.1.6.2.3 Canada Anti-Infective Drugs Market by Indication
10.1.6.3 Mexico Anti-Infective Drugs Market
10.1.6.3.1 Mexico Anti-Infective Drugs Market by Drug Type
10.1.6.3.2 Mexico Anti-Infective Drugs Market by Route of Administration
10.1.6.3.3 Mexico Anti-Infective Drugs Market by Indication
10.2. EUROPE
10.2.1 Europe Anti-Infective Drugs Market Overview
10.2.2 Europe Anti-Infective Drugs Market Forecasts and Analysis
10.2.3 Europe Anti-Infective Drugs Market Forecasts and Analysis - By Drug Type
10.2.4 Europe Anti-Infective Drugs Market Forecasts and Analysis - By Route of Administration
10.2.5 Europe Anti-Infective Drugs Market Forecasts and Analysis - By Indication
10.2.6 Europe Anti-Infective Drugs Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Anti-Infective Drugs Market
10.2.6.1.1 Germany Anti-Infective Drugs Market by Drug Type
10.2.6.1.2 Germany Anti-Infective Drugs Market by Route of Administration
10.2.6.1.3 Germany Anti-Infective Drugs Market by Indication
10.2.6.2 France Anti-Infective Drugs Market
10.2.6.2.1 France Anti-Infective Drugs Market by Drug Type
10.2.6.2.2 France Anti-Infective Drugs Market by Route of Administration
10.2.6.2.3 France Anti-Infective Drugs Market by Indication
10.2.6.3 Italy Anti-Infective Drugs Market
10.2.6.3.1 Italy Anti-Infective Drugs Market by Drug Type
10.2.6.3.2 Italy Anti-Infective Drugs Market by Route of Administration
10.2.6.3.3 Italy Anti-Infective Drugs Market by Indication
10.2.6.4 Spain Anti-Infective Drugs Market
10.2.6.4.1 Spain Anti-Infective Drugs Market by Drug Type
10.2.6.4.2 Spain Anti-Infective Drugs Market by Route of Administration
10.2.6.4.3 Spain Anti-Infective Drugs Market by Indication
10.2.6.5 United Kingdom Anti-Infective Drugs Market
10.2.6.5.1 United Kingdom Anti-Infective Drugs Market by Drug Type
10.2.6.5.2 United Kingdom Anti-Infective Drugs Market by Route of Administration
10.2.6.5.3 United Kingdom Anti-Infective Drugs Market by Indication
10.2.6.6 Rest of Europe Anti-Infective Drugs Market
10.2.6.6.1 Rest of Europe Anti-Infective Drugs Market by Drug Type
10.2.6.6.2 Rest of Europe Anti-Infective Drugs Market by Route of Administration
10.2.6.6.3 Rest of Europe Anti-Infective Drugs Market by Indication
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Anti-Infective Drugs Market Overview
10.3.2 Asia-Pacific Anti-Infective Drugs Market Forecasts and Analysis
10.3.3 Asia-Pacific Anti-Infective Drugs Market Forecasts and Analysis - By Drug Type
10.3.4 Asia-Pacific Anti-Infective Drugs Market Forecasts and Analysis - By Route of Administration
10.3.5 Asia-Pacific Anti-Infective Drugs Market Forecasts and Analysis - By Indication
10.3.6 Asia-Pacific Anti-Infective Drugs Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Anti-Infective Drugs Market
10.3.6.1.1 Australia Anti-Infective Drugs Market by Drug Type
10.3.6.1.2 Australia Anti-Infective Drugs Market by Route of Administration
10.3.6.1.3 Australia Anti-Infective Drugs Market by Indication
10.3.6.2 China Anti-Infective Drugs Market
10.3.6.2.1 China Anti-Infective Drugs Market by Drug Type
10.3.6.2.2 China Anti-Infective Drugs Market by Route of Administration
10.3.6.2.3 China Anti-Infective Drugs Market by Indication
10.3.6.3 India Anti-Infective Drugs Market
10.3.6.3.1 India Anti-Infective Drugs Market by Drug Type
10.3.6.3.2 India Anti-Infective Drugs Market by Route of Administration
10.3.6.3.3 India Anti-Infective Drugs Market by Indication
10.3.6.4 Japan Anti-Infective Drugs Market
10.3.6.4.1 Japan Anti-Infective Drugs Market by Drug Type
10.3.6.4.2 Japan Anti-Infective Drugs Market by Route of Administration
10.3.6.4.3 Japan Anti-Infective Drugs Market by Indication
10.3.6.5 South Korea Anti-Infective Drugs Market
10.3.6.5.1 South Korea Anti-Infective Drugs Market by Drug Type
10.3.6.5.2 South Korea Anti-Infective Drugs Market by Route of Administration
10.3.6.5.3 South Korea Anti-Infective Drugs Market by Indication
10.3.6.6 Rest of Asia-Pacific Anti-Infective Drugs Market
10.3.6.6.1 Rest of Asia-Pacific Anti-Infective Drugs Market by Drug Type
10.3.6.6.2 Rest of Asia-Pacific Anti-Infective Drugs Market by Route of Administration
10.3.6.6.3 Rest of Asia-Pacific Anti-Infective Drugs Market by Indication
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Anti-Infective Drugs Market Overview
10.4.2 Middle East and Africa Anti-Infective Drugs Market Forecasts and Analysis
10.4.3 Middle East and Africa Anti-Infective Drugs Market Forecasts and Analysis - By Drug Type
10.4.4 Middle East and Africa Anti-Infective Drugs Market Forecasts and Analysis - By Route of Administration
10.4.5 Middle East and Africa Anti-Infective Drugs Market Forecasts and Analysis - By Indication
10.4.6 Middle East and Africa Anti-Infective Drugs Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Anti-Infective Drugs Market
10.4.6.1.1 South Africa Anti-Infective Drugs Market by Drug Type
10.4.6.1.2 South Africa Anti-Infective Drugs Market by Route of Administration
10.4.6.1.3 South Africa Anti-Infective Drugs Market by Indication
10.4.6.2 Saudi Arabia Anti-Infective Drugs Market
10.4.6.2.1 Saudi Arabia Anti-Infective Drugs Market by Drug Type
10.4.6.2.2 Saudi Arabia Anti-Infective Drugs Market by Route of Administration
10.4.6.2.3 Saudi Arabia Anti-Infective Drugs Market by Indication
10.4.6.3 U.A.E Anti-Infective Drugs Market
10.4.6.3.1 U.A.E Anti-Infective Drugs Market by Drug Type
10.4.6.3.2 U.A.E Anti-Infective Drugs Market by Route of Administration
10.4.6.3.3 U.A.E Anti-Infective Drugs Market by Indication
10.4.6.4 Rest of Middle East and Africa Anti-Infective Drugs Market
10.4.6.4.1 Rest of Middle East and Africa Anti-Infective Drugs Market by Drug Type
10.4.6.4.2 Rest of Middle East and Africa Anti-Infective Drugs Market by Route of Administration
10.4.6.4.3 Rest of Middle East and Africa Anti-Infective Drugs Market by Indication
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Anti-Infective Drugs Market Overview
10.5.2 South and Central America Anti-Infective Drugs Market Forecasts and Analysis
10.5.3 South and Central America Anti-Infective Drugs Market Forecasts and Analysis - By Drug Type
10.5.4 South and Central America Anti-Infective Drugs Market Forecasts and Analysis - By Route of Administration
10.5.5 South and Central America Anti-Infective Drugs Market Forecasts and Analysis - By Indication
10.5.6 South and Central America Anti-Infective Drugs Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Anti-Infective Drugs Market
10.5.6.1.1 Brazil Anti-Infective Drugs Market by Drug Type
10.5.6.1.2 Brazil Anti-Infective Drugs Market by Route of Administration
10.5.6.1.3 Brazil Anti-Infective Drugs Market by Indication
10.5.6.2 Argentina Anti-Infective Drugs Market
10.5.6.2.1 Argentina Anti-Infective Drugs Market by Drug Type
10.5.6.2.2 Argentina Anti-Infective Drugs Market by Route of Administration
10.5.6.2.3 Argentina Anti-Infective Drugs Market by Indication
10.5.6.3 Rest of South and Central America Anti-Infective Drugs Market
10.5.6.3.1 Rest of South and Central America Anti-Infective Drugs Market by Drug Type
10.5.6.3.2 Rest of South and Central America Anti-Infective Drugs Market by Route of Administration
10.5.6.3.3 Rest of South and Central America Anti-Infective Drugs Market by Indication
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL ANTI-INFECTIVE DRUGS MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. ANTI-INFECTIVE DRUGS MARKET, KEY COMPANY PROFILES
13.1. MERCK AND CO., INC
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. F. HOFFMANN-LA ROCHE LTD
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. PFIZER INC
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. JOHNSON AND JOHNSON SERVICES, INC
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. GLAXOSMITHKLINE PLC
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. HETERO
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. MYLAN N.V.
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. AUROBINDO PHARMA
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. CIPLA INC
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. LAURUS LABS LTD
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
1. Merck & Co., Inc
2. F. Hoffmann-La Roche Ltd
3. Pfizer Inc
4. Johnson & Johnson Services, Inc
5. GlaxoSmithKline plc
6. Hetero
7. Mylan N.V.
8. Aurobindo Pharma
9. Cipla Inc
10. Laurus Labs Ltd
11. Micro Labs Ltd, Inc
12. Gilead Sciences, Inc
13. Sun Pharmaceutical Industries Ltd
14. Amneal Pharmaceuticals LLC
15. Alembic Pharmaceuticals Limited
16. Lupin
17. Novartis AG
18. Zydus Pharma
19. Bausch Health
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For